When a thyroid nodule or other finding raises concern for thyroid cancer, several nuclear medicine and related tests may be used, alongside ultrasound and fine-needle aspiration biopsy, to characterize the nodule and plan treatment.
A thyroid scan uses a small dose of a radioactive tracer (commonly iodine-123 or technetium-99m) to show which parts of the thyroid gland are overactive (“hot” nodules, which are usually, though not always, benign) and which are underactive (“cold” nodules, which carry a somewhat higher likelihood of malignancy and more often require biopsy). The scan itself is painless, requires only lying still under the camera for a short period after the tracer is given, and carries a very small radiation dose.
After thyroid cancer has been diagnosed and treated, a whole-body iodine scan may be performed, usually in conjunction with radioactive iodine treatment, to check for any remaining normal thyroid tissue or metastatic cancer cells elsewhere in the body that take up iodine. In follow-up after treatment, a blood test for thyroglobulin (a protein produced only by thyroid tissue) is used as a tumor marker: after a total thyroidectomy and successful radioactive iodine treatment, thyroglobulin should fall to a very low or undetectable level, and a later rise can be an early sign of recurrence, prompting further imaging. Your referring physician will determine which combination of these tests, along with regular clinical examination and ultrasound, is appropriate for your specific case and stage of follow-up.

